Hydrogen Therapy Shows Promise for Arthritis and Muscle Pain Relief

Authors
Journal
World Journal of Orthopedics
Year
DOI
10.5312/wjo.v17.i1.111911
Study Type
clinical
Peer Reviewed
Yes
Country
India
Health Condition
Osteoarthritis
Body System
Musculoskeletal

TL;DR

Scientists tested whether hydrogen gas could help people with joint and muscle problems like arthritis and muscle pain, and early results look pretty good—it seems to reduce swelling and damage in the body. But they need to do bigger, better-designed studies to prove it actually works before doctors can recommend it as a real treatment.

Key Finding

Preclinical studies consistently showed hydrogen reduced harmful inflammatory markers and improved cell survival, while clinical trials reported symptomatic relief in osteoarthritis and rheumatoid arthritis, but significant limitations in study design prevent definitive conclusions about effectiveness.

Summary

This review examined 45 studies (25 in animals/cells and 20 in humans) on whether molecular hydrogen—a gas that can be delivered through water, inhalation, or injection—might help with joint and muscle problems like arthritis and muscle damage. Animal studies consistently showed that hydrogen reduced harmful molecules called reactive oxygen species and inflammatory markers in cells. Human trials reported some symptom improvement in osteoarthritis and rheumatoid arthritis patients, though the studies varied widely in how they delivered hydrogen and measured results, making it hard to draw firm conclusions.

Practical Takeaway

Early evidence suggests hydrogen water may have anti-inflammatory potential for musculoskeletal conditions, but current research is limited by small sample sizes, short study durations, and inconsistent methods across trials. Much larger, longer, and more standardized human studies are needed before hydrogen can be recommended as a proven treatment for arthritis or muscle damage.

Abstract

Molecular hydrogen (H2) demonstrates selective antioxidant and anti-inflammatory properties with therapeutic potential across musculoskeletal conditions including osteoarthritis, rheumatoid arthritis, exercise-induced muscle damage, chronic pain syndromes, tendinopathies, and muscle atrophy. This review critically evaluates preclinical and clinical evidence for H2 therapy and identifies research gaps. A comprehensive search of PubMed, EMBASE, and Cochrane Library (up to April 2025) yielded 45 eligible studies: 25 preclinical and 20 clinical trials. Preclinical models consistently showed reductions in reactive oxygen species, inflammatory cytokines, and improved cell viability. Clinical trials reported symptomatic relief in osteoarthritis, decreased Disease Activity Score 28 in rheumatoid arthritis, and accelerated clearance of muscle damage markers. Delivery methods varied - hydrogen-rich water, gas inhalation, and saline infusion - hindering direct comparison. Mechanistic biomarkers were inconsistently reported, limiting understanding of target engagement. Common limitations included small sample sizes, short durations, and protocol heterogeneity. Despite these constraints, findings suggest H2 may serve as a promising adjunctive therapy via antioxidant, anti-inflammatory, and cytoprotective mechanisms. Future research should prioritize standardized delivery protocols, robust mechanistic endpoints, and longer-term randomized trials to validate clinical efficacy and optimize therapeutic strategies.